Could a cholesterol drug boost reading skills in kids with NF1?
NCT ID NCT02964884
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study investigates whether combining the medication lovastatin with intensive reading tutoring can improve reading abilities in children and young adults (ages 8-20) with Neurofibromatosis Type 1 (NF1) who have reading disabilities. Participants first receive either lovastatin or a placebo daily for 12 weeks, then undergo one week of specialized reading or sham tutoring. The goal is to see if the medication enhances the brain's response to tutoring by targeting a protein deficiency linked to learning and memory in NF1.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lovastatin
What this could lead to
If it works, this could point toward a treatment that combines medication with tutoring to improve reading skills in children with NF1.
What could go wrong
This is a Phase 2 study with a small number of participants, so results may not apply to everyone. Lovastatin may cause side effects like muscle pain or digestive issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University
Nashville, Tennessee, United States